Jens D. Lundgren
Expertise in
15
conditions

Jens D. Lundgren

Copenhagen, DK 
Expertise in
15
conditions
Copenhagen, DK 

Overview

Jens Lundgren practices practicing medicine in Copenhagen, Denmark.

Mr. Lundgren is highly rated in 15 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Cytomegalovirus Infection, Severe Acute Respiratory Syndrome (SARS), Bone Marrow Transplant, and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 454 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Copenhagen, Denmark
Other Locations
Hvidovre, Denmark
Skejby, Denmark
Herlev, 8632, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
An International Observational Study of Outpatients With SARS-CoV-2 Infection
An International Observational Study of Outpatients With SARS-CoV-2 Infection
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Other
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Hyperimmune immunoglobulin to SARS-CoV-2, Remdesivir
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
Enrollment Status: Completed
Publish Date: November 01, 2019
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 5 Less Clinical Trials

450 Total Publications

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.
Journal: Critical care medicine
Published: May 26, 2026

Frequently Asked Questions about Jens D. Lundgren

Is Jens D. Lundgren a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Jens D. Lundgren is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jens D. Lundgren participate in research or clinical trials?

Yes. Jens D. Lundgren has published 450 articles and abstracts on conditions like HIV/AIDS. You can view a list of Jens D. Lundgren's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lundgren's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 49 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile